These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31848044)

  • 1. Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.
    Tong K; Barker D; France M; Burr L; Greville H; Visser S; Middleton P; Wainwright C; Dorahy D; Wark P
    J Cyst Fibros; 2020 May; 19(3):415-420. PubMed ID: 31848044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
    Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease.
    Popowicz N; Wood J; Tai A; Morey S; Mulrennan S
    J Cyst Fibros; 2017 May; 16(3):392-394. PubMed ID: 28314539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal changes in lung function following initiation of lumacaftor/ivacaftor combination.
    Loukou I; Moustaki M; Plyta M; Douros K
    J Cyst Fibros; 2020 Jul; 19(4):534-539. PubMed ID: 31676345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
    Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
    Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
    Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
    Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV
    Aalbers BL; de Winter-de Groot KM; Arets HGM; Hofland RW; de Kiviet AC; van Oirschot-van de Ven MMM; Kruijswijk MA; Schotman S; Michel S; van der Ent CK; Heijerman HGM
    J Cyst Fibros; 2020 Jul; 19(4):654-658. PubMed ID: 31924546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
    Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D;
    Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
    Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
    N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination.
    Pócsi M; Fejes Z; Bene Z; Nagy A; Balogh I; Amaral MD; Macek M; Nagy B
    J Cyst Fibros; 2023 Nov; 22(6):1085-1092. PubMed ID: 37087300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis.
    Habib AR; Kajbafzadeh M; Desai S; Yang CL; Skolnik K; Quon BS
    Sci Rep; 2019 May; 9(1):7234. PubMed ID: 31076617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.
    Sagel SD; Khan U; Heltshe SL; Clancy JP; Borowitz D; Gelfond D; Donaldson SH; Moran A; Ratjen F; VanDalfsen JM; Rowe SM
    Ann Am Thorac Soc; 2021 Jan; 18(1):75-83. PubMed ID: 32644818
    [No Abstract]   [Full Text] [Related]  

  • 15. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compassionate Use of Lumacaftor/Ivacaftor in Cystic Fibrosis: Spanish Experience.
    Diab-Cáceres L; Girón-Moreno RM; Pastor-Sanz MT; Quintana-Gallego E; Delgado-Pecellín I; Blanco-Aparicio M; Maiz L; García-Clemente MM; Luna-Paredes C; Mondéjar-López P; Ruiz-de-Valbuena M; Fernández O; Barrio M; González M; López-Neyra A; Cols-I-Roig M; Palou-Rotger A; Gómez-de-Terreros-Caro FJ
    Arch Bronconeumol (Engl Ed); 2018 Dec; 54(12):614-618. PubMed ID: 30518496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).
    van Koningsbruggen-Rietschel S; Conrath K; Fischer R; Sutharsan S; Kempa A; Gleiber W; Schwarz C; Hector A; Van Osselaer N; Pano A; Corveleyn S; Bwirire D; Santermans E; Muller K; Bellaire S; Van de Steen O
    J Cyst Fibros; 2020 Mar; 19(2):292-298. PubMed ID: 31594690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
    Tesell MA; Alper CJ; Bacon R; Greenwood BC; Lenz K; Jeffrey PL; Stevens K
    J Manag Care Spec Pharm; 2019 Sep; 25(9):1021-1025. PubMed ID: 31456498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
    Berkers G; van der Meer R; Heijerman H; Beekman JM; Boj SF; Vries RGJ; van Mourik P; Doyle JR; Audhya P; Yuan ZJ; Kinnman N; van der Ent CK
    J Cyst Fibros; 2021 Sep; 20(5):761-767. PubMed ID: 33249003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.